Research programme: factor IXa inhibitors - Trigen

Drug Profile

Research programme: factor IXa inhibitors - Trigen

Alternative Names: Factor IXa inhibitors research programme - Trigen

Latest Information Update: 16 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trigen Holdings AG
  • Class Small molecules
  • Mechanism of Action Factor IXa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 21 Feb 2008 This programme is still in active development
  • 03 Aug 2005 This programme is still in active development - (BIO-2005)
  • 31 May 2005 ProCorde GmbH has merged with Trigen Holdings plc to form Trigen Holdings AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top